NCT01670513View on ClinicalTrials.gov

A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

July 31, 2013

Conditions
Plaque Psoriasis
Interventions
DRUG

IDP-118 Low Strength

8 weeks

DRUG

IDP-118 High Strength

8 weeks

Trial Locations (6)

23507

Dow Clinical Study Site, Norfolk

37215

Dow Clinical Study Site, Nashville

48038

Dow Clinical Study Site, Clinton Township

48059

Dow Cliincal Study Site, Fort Gratiot

78759

Dow Clinical Study Site, Austin

95403

Dow Clinical Study Site, Santa Rosa

Sponsors
All Listed Sponsors
lead

Dow Pharmaceutical Sciences

INDUSTRY